The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Solid Tumor Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
In cancer, solid tumors are formed by aggregation of abnormal tissues that do not comprise of any liquid or cyst.
The global Solid Tumor Therapeutics market size is expected to reach US$ 215470 million by 2029, growing at a CAGR of 8.5% from 2023 to 2029. The market is mainly driven by the significant applications of Solid Tumor Therapeutics in various end use industries. The expanding demands from the Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer, are propelling Solid Tumor Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormone Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Solid Tumor Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Solid Tumor Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Solid Tumor Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Solid Tumor Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Solid Tumor Therapeutics covered in this report include Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly and Kyowa Hakko Kirin, etc.
The global Solid Tumor Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Hoffmann-La Roche
Johnson & Johnson
Novartis
AstraZeneca
Biogen Idec
Boehringer Ingelheim
GlaxoSmithKline
Eli Lilly
Kyowa Hakko Kirin
Abbott Laboratories
Baxter International
Global Solid Tumor Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Solid Tumor Therapeutics market, Segment by Type:
Chemotherapy
Hormone Therapy
Immunotherapy
Targeted Therapy
Global Solid Tumor Therapeutics market, by Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Solid Tumor Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
In cancer, solid tumors are formed by aggregation of abnormal tissues that do not comprise of any liquid or cyst.
The global Solid Tumor Therapeutics market size is expected to reach US$ 215470 million by 2029, growing at a CAGR of 8.5% from 2023 to 2029. The market is mainly driven by the significant applications of Solid Tumor Therapeutics in various end use industries. The expanding demands from the Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer, are propelling Solid Tumor Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hormone Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Solid Tumor Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Solid Tumor Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Solid Tumor Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Solid Tumor Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Solid Tumor Therapeutics covered in this report include Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly and Kyowa Hakko Kirin, etc.
The global Solid Tumor Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Hoffmann-La Roche
Johnson & Johnson
Novartis
AstraZeneca
Biogen Idec
Boehringer Ingelheim
GlaxoSmithKline
Eli Lilly
Kyowa Hakko Kirin
Abbott Laboratories
Baxter International
Global Solid Tumor Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Solid Tumor Therapeutics market, Segment by Type:
Chemotherapy
Hormone Therapy
Immunotherapy
Targeted Therapy
Global Solid Tumor Therapeutics market, by Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Solid Tumor Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Solid Tumor Therapeutics
1.1 Solid Tumor Therapeutics Market Overview
1.1.1 Solid Tumor Therapeutics Product Scope
1.1.2 Solid Tumor Therapeutics Market Status and Outlook
1.2 Global Solid Tumor Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Solid Tumor Therapeutics Market Size by Region (2018-2029)
1.4 Global Solid Tumor Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Solid Tumor Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Solid Tumor Therapeutics Market Size (2018-2029)
1.6.1 North America Solid Tumor Therapeutics Market Size (2018-2029)
1.6.2 Europe Solid Tumor Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Solid Tumor Therapeutics Market Size (2018-2029)
1.6.4 Latin America Solid Tumor Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Solid Tumor Therapeutics Market Size (2018-2029)
2 Solid Tumor Therapeutics Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Hormone Therapy
2.1.3 Immunotherapy
2.1.4 Targeted Therapy
2.2 Global Solid Tumor Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Solid Tumor Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Solid Tumor Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Solid Tumor Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Solid Tumor Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Solid Tumor Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Solid Tumor Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Solid Tumor Therapeutics Revenue Breakdown by Type (2018-2029)
3 Solid Tumor Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Breast Cancer
3.1.2 Lung Cancer
3.1.3 Colorectal Cancer
3.1.4 Prostate Cancer
3.1.5 Cervical Cancer
3.1.6 Others
3.2 Global Solid Tumor Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Solid Tumor Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Solid Tumor Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Solid Tumor Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Solid Tumor Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Solid Tumor Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Solid Tumor Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Solid Tumor Therapeutics Revenue Breakdown by Application (2018-2029)
4 Solid Tumor Therapeutics Competition Analysis by Players
4.1 Global Solid Tumor Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Solid Tumor Therapeutics as of 2022)
4.3 Date of Key Players Enter into Solid Tumor Therapeutics Market
4.4 Global Top Players Solid Tumor Therapeutics Headquarters and Area Served
4.5 Key Players Solid Tumor Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Solid Tumor Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Hoffmann-La Roche
5.1.1 Hoffmann-La Roche Profile
5.1.2 Hoffmann-La Roche Main Business
5.1.3 Hoffmann-La Roche Solid Tumor Therapeutics Products, Services and Solutions
5.1.4 Hoffmann-La Roche Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Hoffmann-La Roche Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Solid Tumor Therapeutics Products, Services and Solutions
5.2.4 Johnson & Johnson Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Johnson & Johnson Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Solid Tumor Therapeutics Products, Services and Solutions
5.3.4 Novartis Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 AstraZeneca Recent Developments
5.4 AstraZeneca
5.4.1 AstraZeneca Profile
5.4.2 AstraZeneca Main Business
5.4.3 AstraZeneca Solid Tumor Therapeutics Products, Services and Solutions
5.4.4 AstraZeneca Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 AstraZeneca Recent Developments
5.5 Biogen Idec
5.5.1 Biogen Idec Profile
5.5.2 Biogen Idec Main Business
5.5.3 Biogen Idec Solid Tumor Therapeutics Products, Services and Solutions
5.5.4 Biogen Idec Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Biogen Idec Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Solid Tumor Therapeutics Products, Services and Solutions
5.6.4 Boehringer Ingelheim Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 GlaxoSmithKline
5.7.1 GlaxoSmithKline Profile
5.7.2 GlaxoSmithKline Main Business
5.7.3 GlaxoSmithKline Solid Tumor Therapeutics Products, Services and Solutions
5.7.4 GlaxoSmithKline Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 GlaxoSmithKline Recent Developments
5.8 Eli Lilly
5.8.1 Eli Lilly Profile
5.8.2 Eli Lilly Main Business
5.8.3 Eli Lilly Solid Tumor Therapeutics Products, Services and Solutions
5.8.4 Eli Lilly Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Eli Lilly Recent Developments
5.9 Kyowa Hakko Kirin
5.9.1 Kyowa Hakko Kirin Profile
5.9.2 Kyowa Hakko Kirin Main Business
5.9.3 Kyowa Hakko Kirin Solid Tumor Therapeutics Products, Services and Solutions
5.9.4 Kyowa Hakko Kirin Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Kyowa Hakko Kirin Recent Developments
5.10 Abbott Laboratories
5.10.1 Abbott Laboratories Profile
5.10.2 Abbott Laboratories Main Business
5.10.3 Abbott Laboratories Solid Tumor Therapeutics Products, Services and Solutions
5.10.4 Abbott Laboratories Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Abbott Laboratories Recent Developments
5.11 Baxter International
5.11.1 Baxter International Profile
5.11.2 Baxter International Main Business
5.11.3 Baxter International Solid Tumor Therapeutics Products, Services and Solutions
5.11.4 Baxter International Solid Tumor Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Baxter International Recent Developments
6 North America
6.1 North America Solid Tumor Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Solid Tumor Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Solid Tumor Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Solid Tumor Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Solid Tumor Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Solid Tumor Therapeutics Market Dynamics
11.1 Solid Tumor Therapeutics Industry Trends
11.2 Solid Tumor Therapeutics Market Drivers
11.3 Solid Tumor Therapeutics Market Challenges
11.4 Solid Tumor Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
